Biomedical and great health come to the "wind" to dance and dance a few cities

Zhuzhou Daily All Media Reporter/Li Jun Liu Fangyi

Core tip

"The 21st century is the century of creatures."

The rapid development of the current biological economy is gradually verifying the accuracy of this prophecy.

The report of the 19th National Congress of the Communist Party of China proposed that "implementing a healthy China strategy." In May of this year, my country released the first five -year planning of biological economy to clearly develop four key areas including biomedicine. At the same time, it is emphasized that the development of biomedicine must adapt to the new trend of "health -centric".

Those who inspect the potential, and those who control the potential win.

Zhuzhou established 13 emerging advantageous industrial chains this year. Among them, the biomedical and large health industry chain is optimized from the original biomedical industry chain.

Take advantage of the development. This time we sort out the experience of promoting the biomedicine and the large health industry in Suzhou, Guangzhou, Shanghai and Wuhan to learn from Zhuzhou.

【Industrial Chain Business Card】

In 2021, Zhuzhou Biomedical and the Big Health Industry scale was 7.4 billion yuan, with 71 upstream and downstream companies, 1 listed company, and 5 "little giants" enterprises in the country. Zhongsheng's first biochemical compression technology (PCT) fills domestic and foreign peptide library building technology gaps. In 2025, Zhuzhou will build a famous biomedical health industry with certain influence at home and abroad.

Qianjin employees work in Hexi Capsule Packaging Workshop. (Photo Conferring in Qianjin Group)

Suzhou: Forward -looking layout, gather innovation elements to achieve "curve overtaking"

【Industrial Chain Business Card】

As of 2021, Suzhou has gathered more than 4,300 biomedical companies, and the city's biomedical and medical equipment regulations have 450 enterprises, and the industry scale exceeds 240 billion yuan. At present, Suzhou Industrial Park alone has gathered 85 listed companies and innovative leading enterprises in the field of biomedicine, accounting for more than 20%in similar companies in the country.

From the former "one poor and two white", it ranked first in the country. The biomedical industry in Suzhou has been promoted to catch up with advance thinking to gather innovation elements to improve the industrial ecology, forming a unique "Suzhou model".

How strong is the biomedical industry in Suzhou?

In the ranking of the competitiveness of the China Biomedical Industrial Park released by the China Biotechnology Development Center, the comprehensive competitiveness of Suzhou Industrial Park and the three special competitiveness of the industry, talent, and technology are ranked first in the country. Suzhou Biomedical Industry was selected into the first batch of national strategic emerging industrial clusters and was approved by the first national technological innovation center in the national biomedical field.

Interestingly, Suzhou does not have the advantage of "grabbing" on the biomedical industry track, but on the contrary, it is a "rising star". 16 years ago in Suzhou, there was no strong medical heritage, no leading pharmaceutical companies, and lack of clinical resources such as comprehensive hospitals.

From the "zero" breakthrough and strong rise, the "Suzhou model" of the development of the biomedical industry has its own unique experience: relying on strong government resources, but fully acts in accordance with market -oriented rules. Essence

In 2006, the Biobay of Suzhou Biopharmaceutical Park broke the soil. Its rising road condensed the essence of the development of Suzhou biomedical industry. In terms of operating models, venture capital settings and brand building, it has pioneering exploration.

Biobay uses corporate operation in the background of the government to establish a market -oriented team with industrial thinking and professional capabilities. On March 22, 2006, Biobao started in the morning. The parent fund was the first RMB parent fund in China's market -oriented operation, which was 1 billion yuan at that time.

At that time, the domestic pharmaceutical industry imitations, but BioBay chose to take the road of biopharmaceutical development in advance. When attracting the project, Biobao did not take taxes and the number of employment as the main consideration. The park's investment personnel all participated in various conferences around the world to dig out "good seedlings" and relying on the clumsy methods to come to the door to stare, we ushered in the first new team and startups of high -end technology in the park.

BioBay's project attraction strategy has allowed a group of head enterprises in the field of domestic biomedicine, including Cinda Bio, Baiji Shenzhou, and Cornerstone Pharmaceuticals. Industrial clusters.

The settlement of the Lengquan Port Asian Conference Center is a major turning point for BIOBAY to achieve the "innovative element cluster", and also allows Suzhou to achieve "curve overtaking" in the biomedical field.

The Lengquan Port Lab is known as the cradle of the sanctuary and molecular biology of the world's life sciences. Through the overcome difficulties, in 2007, Suzhou Industrial Park and the Lengquan Port Lab signed a cooperation agreement to establish the Asian Conference Center of Lengquan Port. In the century -old history of Lengquan Port Lab, this is its first branch in overseas. Since then, hundreds of high -end academic conferences, about 20 Nobel Prize winners, have gradually launched the brand.

"This idea is definitely ahead. It takes a lot of funds to introduce a meeting that may not be directly contributed to GDP growth. Fei Jianjiang, a partner of Yuanhe origin in Suzhou Industrial Park, lamented.

Guangzhou: The entire industry chain is enabled to enable leapfrog development

【Industrial Chain Business Card】

In recent years, the average annual growth of the biopharmaceutical industry in Guangzhou has reached about 10%. There are more than 6,400 biomedical companies in various types, ranking third in the country, 47 listed companies, and fourth in the country. Five Nobel Prize winners, 40 academicians, and 229 major national talent projects were gathered in the field of biomedicine. Guangyao Group is the first company to enter the Fortune 500 in the world's main business. Regardless of the size of the industry, the number of enterprises, or the innovation platform, the Guangzhou biomedical industry has ranked among the country's first echelon. Behind the leap -up development is the continuous empowerment of the upstream R & D tests, midstream trial production, and downstream listing and sales of the entire industrial chain.

In the middle of the Guangzhou Pearl River Channel, Guangzhou International Bioshima wrote a legend: 11 years ago, this island village was still unknown; today, 11 years later, it has become the core engine of the Guangzhou biomedical industry.

Within 1.83 square kilometers, more than ten years, Guangzhou International Bioshima has gathered more than 500 biomedical companies, of which 4 listed companies headquarters in Bioshima are 800 projects such as Astrakan and Merkees. There are more than 30 academicians such as Xu Tao and Wang Yingjun, and the biomedical industry is booming here.

Looking at Guangzhou through Bioshima, Guangzhou is also like a "raw" machine "island": In recent years, Guangzhou has established multiple platforms, gather upstream and downstream enterprises, build industry -university -research sets, and promote the biomedical industry in the entire industry chain. The industrial ecology of "small and beautiful", "specialty", "strong and excellent".

"Small and beautiful" refers to the company with a small amount of strong research and development.

Earlier this year, Guangzhou's quasi -unicorn enterprise announced that Yinming Bio announced in Guangzhou to build a global innovative medicine headquarters and research and development center. In the two years since its establishment, the company has focused on the development of original innovation medicines. There have been three products in clinical experiments and completed two rounds of nearly $ 110 million in financing last year. When biotechnology continues to open up the Xinjiang domain, in Guangzhou, there are still many such "small and beautiful" biomedical companies that are rising. Although they are not large, they have strong R & D strength and amazing valuation.

"Specialized and fine" refers to the "star" enterprise in the professional segment, and also refers to the new track that can be developed.

In April of this year, the "Implementation Plan for Accelerating the Development of the Medical Inspection Industry Cluster" proposed that during the "Fourteenth Five -Year Plan" period, Guangzhou will strive to build a 100 billion -level medical test industry cluster, build a medical test industry highland, cast the biomedical industry "New Business Card".

In 2021, the scale of Guangzhou's medical inspection industry was nearly 50 billion yuan, and industry leading enterprises represented by Jinyu Medicine, Daannin, Wanfu Biological, etc. emerged. The business covered the country and even radiated the world.

"Strong and excellent" refers to the world's Fortune 500 companies' "feeding" biotechnology innovation.

For example, after Guangzhou International Bioshima has attracted a number of Fortune 500 biomedical companies to settle in, showing a trend of clusterization of major industrial regional clustering, and these companies in turn promoted further innovation in Guangzhou Biomedical Technology.

In 2021, the Baiji Shenzhou Bioshima Innovation Center was established. As an incubator with innovation as the core, the Innovation Center will provide advanced equipment, scientific and commercial guidance for the development of startups, and accelerate the source innovation of scientists and entrepreneurs. This means that in the fifth year of the connection between Baiji Shenzhou and Guangzhou, the layout has formed a closed -loop research, production, and sales value chain.

Today, the Guangzhou biomedical industry has formed a development pattern of R & D in the “three central centers of radiation multi -regional” industry chain in the Knowledge City. In addition, in different nodes of the city, related industrial parks grow up and grow, and jointly promote Guangzhou to form a global layout, focusing on each other, mutual collaborative, and distinctive biomedical and health industry spatial patterns.

Shanghai: Disted Development to build a Chinese "Panyin Valley"

【Industrial Chain Business Card】

In 2021, the scale of Shanghai's biomedical industry was 761.714 billion yuan, accounting for about one -sixth of Shanghai's total GDP, a record high, of which the manufacturing output value was 171.2 billion yuan, a year -on -year increase of 12%. As of the end of 2021, there were 6066 biomedical related companies in Shanghai. High -end talents and innovative drug talents such as academicians and Yangtze River scholars accounted for one quarter of the country. Among the top 20 pharmaceutical companies in the world, 17 are located in Shanghai.

In recent years, Shanghai has implemented the "Zhangjiang R & D+Made in Shanghai" strategy to form a "focusing Zhangjiang, one nuclear point" biomedical industry spatial pattern focusing on Zhangjiang as the core, Jinshan, Fengxian, Xuhui and other parks. Development and advantages complement each other, and build China's "Panying Valley".

As the birthplace of China's modern biomedical industry, Shanghai has always had an attitude and ambition.

As early as 1994, Shanghai clarified its industrial positioning and proposed to build China's "Panyin Valley" in Zhangjiang to promote the pharmaceutical industry as a key industry.

In August 1999, Shanghai released the development strategy of "focusing on Zhangjiang", developed Zhangjiang in the city, and then established the Shanghai Modern Biological and Pharmaceutical Industry Office.

The benchmarking Silicon Valley in the United States has spent a lot of effort: rail transit was directly repaired to the center of the park, and the Shanghai Academy of Sciences Shanghai Pharmaceutical Institute, Fudan University Academy of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai Pharmaceutical Group Research Institute, Shanghai Medical Industry Research Institute, etc. Move to Zhangjiang.

The launch of a series of supporting policies has prompted head enterprises in the field of biomedicine to settle in Zhangjiang. At present, Zhangjiang has gathered more than 1,000 biomedical innovation companies. Among the top 10 pharmaceutical companies in the world, 7 have set up regional headquarters and R & D centers in Zhangjiang. One -third of an innovative medicine comes from Zhang Jiang. Although the growth rate of Zhangjiang biomedical industry in recent years is amazing, the international advanced internationally advanced, it still lacks competitiveness.

Further development of the biomedical industry to enhance international competitiveness, Shanghai has released many policies such as the "Implementation Plan on Promoting the Characteristic Development of the Biomedical Industry Park". At the same time, the development path is clear: the implementation of the "Zhangjiang R & D+Shanghai Manufacturing" action, focusing on the construction of the "1+5+X" biomedical industrial park. Among them, "1" refers to the core area of ​​Zhangjiang Biomedical Innovation; "5" represents the precision medical prerequisite demonstration area of ​​the Lingang New Area, the Life Healthy Development Zone (Fengxian), the Golden Coast Modern Pharmaceutical Green Carrier Zone (Jinshan), the Golden Coast Modern Pharmaceutical North Shanghai Biomedical High -end Manufacturing Gathering Area (Baoshan), Nanhong Bridge Smart Medical Innovation Pilot Zone (Minhang); "X" refers to the carrier of biomedical characteristic industries, such as Putuo Ring Tongji Medical College Life and Headquarters Base, Jiading Nanxiang Precision Medicine Industry Garden and Qingpu Chongguhongqiao Medical Devices Increasing Park.

As the "axis" of the biomedical industry map, Zhangjiang Biomedical Innovation Leading the core area of ​​the core area is to give full play to the industrial space advantage of Zhangjiang Innovation Pharmaceutical Industry Base, focusing on the development of the development and transformation manufacturing industry chain of innovative drugs and high -end medical devices , Build an innovation highland with global influence.

Taking Zhangjiang as the "vane", each park is accurately located. For example, there are clear systems and spatial advantages in the new area of ​​Lingang, and focus on focusing on the three major sections of biomedical, high -end medical equipment, and international medical services.

At present, Shanghai has formed the "1+5+X" industrial development layout based on Zhangjiang as the core and supporting five characteristic parks, including the new area of ​​Lingang, and other characteristic bases. Continuously optimized, industrial carrying space continues to improve, and various types of innovation elements have accelerated to gather to industrial parks.

Wuhan: The government has carefully cultivated the growth of the "irrigation" industry

【Industrial Chain Business Card】

Wuhan biomedicine and large health industries are one of the first biopharmaceutical industrial clusters in the country. In recent years, Wuhan has accelerated the industrial layout and established a spatial pattern of "one city, one garden and three districts". Among them, the Optics Valley Biological City is the core of the layout of biomedical and large health industries. As of the end of 2021, there are 704 biomedical related companies in Wuhan, covering five major areas of biomedical, medical equipment, medical circulation, biological agriculture and health services.

Investing in large, high risk, and long cycles, the biomedical and large health industries are called "the most patient industry." Wuhan's biomedicine and large health industries can hatch from "seeds", flowering and fruiting, to bigger and stronger, and government guidance and cultivation are critical.

In recent years, relevant departments of Wuhan have repeatedly introduced support policies to promote the development of the biomedical industry. In November last year, Wuhan released the "Further Promoting Policies and Measures for the Development of Biological Health and Biotechnology Industry" (referred to as the "Measures"). From 18 aspects such as enterprise introduction, new drug research and development, and industrial innovation, it provided great efforts to support funds and policy support.

For example, the "Measures" pointed out that the establishment of Wuhan Great Health and Biotechnology Industry Investment Fund with a total scale of 30 billion yuan will be established to give full play to the leverage of financial funds in the urban area and leveraging various social capital to form a 100 billion -scale fund group.

This cultivation and guidance is not only reflected in "smashing money".

Fourteen years ago, when the core area of ​​Wuhan Biomedical and Large Health Industry -Optics Valley Biological City was laid out, there were 26 national biological industry bases across the country. As the third batch of entrants, how did Wuhan live in?

"Aiming at the high point of the industry system, it is not fast, not greedy for a while, and does not admire the name." Wuhan's functional departments gradually formed a consensus. "Store Little Er", personal service to help companies "stay, survive, and strengthen."

An example is still a good story.

When Shenzhen Huada Gene was settled in Wuhan, when the enterprise needs to apply for a three -type medical device registration certificate, the "Store Primary Er" from the park to the relevant functional departments will accompany the enterprise to the State Drug Administration, and the service will be successfully obtained.

Today, in the ranking of Chinese medical device companies, Shenzhen Mai Rui, Shanghai Lianying and Shenzhen Huada Gene are at the top, second, and sixth positions, coupled with the world's top 500 companies. Settled.

The development of biomedical companies cannot be separated from capital support.

The Optics Valley Biological City has established a "biological innovation" service platform to specialize in the cultivation of capital market cultivation and investment and financing roadshow to improve the docking efficiency of biological city enterprises and capital. At present, hundreds of issues have been held.

Subsequently, under the active striving of the Wuhan government, the Hubei Provincial Government's Financial Office coordinated and coordinated. The Optics Valley Biological City and the Shanghai Stock Exchange signed a contract to jointly build the Shanghai Stock Exchange Capital Market to serve the Hubei Base, and signed a contract with the Shenzhen Stock Exchange to co -build Shenzhen Securities In the exchange of Hubei Capital Market Cultivation Base, enterprises and exchanges have established smooth communication channels.

In 2020, the epidemic raid. The Wuhan government coordinated resources and held an online meeting to ask the Shanghai Stock Exchange to answer questions in the listing of enterprises. Loans received a total of 270 various types of funds exceeding 10 billion yuan. The escorting enterprises seize the international market. Optics Valley Biological City also coordinated the green approval channel of the State Drug Administration. The contract amount of 300 million US dollars.

Wisdom

Building an industrial ecology to promote "life"

Li Jun

When searching for the experience of developing the biomedical industry in Suzhou and other places, a keyword appeared many times: "Boston experience". This means that when we look out, aiming at the role model to learn advanced experience, the role model is also learning from their example, and look at the world to learn from experience, and the hands of "useism" reach the world.

What is "Boston Experience"?

Boston is located in the northeast of the United States. Within 232.1 square kilometers, Harvard University, MIT and other top universities and research institutions have gathered. From the perspective of the industry, the development of the Boston biomedical industry is rooted in research and development capabilities and policy support. It consists of three core elements of college scientific research, top colleges and capital blessings, and a good innovation and entrepreneurial environment.

Looking at the models of urban development biomedicine and large health industries such as Suzhou and Guangzhou, it has not exceeded the scope of "Boston experience". In contrast to the development of Zhuzhou biomedicine and large health industries, although there are leading enterprises and related foundations, there are still many shortcomings that need to be supplemented.

To develop biomedicine, creating a good industrial ecology is the most critical. This is the characteristic of the development of the biomedical industry, and it is also the direction of Zhuzhou's next step. Based on this, the construction of an industrial planning blueprint and a characteristic park is quite important. With a blueprint, you can get up your sleeves at the stage steps. With the position, you can accelerate the convergence of technology, capital, and talent resources, and continuously improve the industrial chain into an industrial ecology.

Create a characteristic park platform, improve key links such as innovation chain, talent chain, financial chain, and service chain, form a closed loop of industrial services, gather innovation elements, Zhuzhou biomedicine and large health industries are multiplied, and they will definitely show the more and more vigorous vitality Essence

Source: Zhuzhou Daily

Review: Luo Xiaoling

Edit: Chen Chen

- END -